SEC Company Response from Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Apr 10, 2020
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: April 10, 2020 · CIK: 0001764013 · Accession: 0001193125-20-103123
AI Filing Summary & Sentiment
File numbers found in text: 333-237627
Letter
IMMUNOVANT, INC.
320 West 37th Street
New York, NY 10018
April 10, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Immunovant, Inc.
Registration Statement on Form S-1
File No. 333-237627
Acceleration Request
Requested Date:
April 14, 2020
Requested Time:
9:00 a.m., Eastern Daylight Time
Ladies and Gentlemen:
The undersigned Registrant hereby requests that the staff of the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective on April 14, 2020, at 9:00 a.m., Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of John McKenna and Alison Haggerty of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Alison Haggerty of Cooley LLP at (212) 479-6596.
Very truly yours,
Immunovant, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
IMMUNOVANT, INC.
320 West 37th Street
New
York, NY 10018
April 10, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of
Corporation Finance
Office of Life Sciences
100 F Street,
N.E.
Washington, D.C. 20549
Re:
Immunovant, Inc.
Registration Statement on
Form S-1
File No. 333-237627
Acceleration Request
Requested Date:
April 14, 2020
Requested Time:
9:00 a.m., Eastern Daylight Time
Ladies and Gentlemen:
The undersigned Registrant hereby requests that the staff of the U.S. Securities and Exchange Commission (the “Commission”) take
appropriate action to cause the above-referenced Registration Statement to become effective on April 14, 2020, at 9:00 a.m., Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally
request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of John McKenna and Alison Haggerty of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with John McKenna of Cooley
LLP, counsel to the Registrant, at (650) 843-5059, or in his absence, Alison Haggerty of Cooley LLP at (212) 479-6596.
Very truly yours,
Immunovant, Inc.
By:
/s/ Peter Salzmann, M.D.
Name: Peter Salzmann, M.D.
Title: Chief Executive Officer
cc:
Pamela Yanchik Connealy, Immunovant, Inc.
W. Bradford Middlekauff, Immunovant, Inc.
Frank F. Rahmani, Cooley LLP
John T. McKenna, Cooley LLP
Alison A. Haggerty, Cooley LLP